Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAC2 small nuclear protein (PRAC2) is a gene highly expressed in the prostate, rectum, colon, and testis; minimal expression is seen in placenta and leukocytes[1][3][6]. The gene is annotated as potentially encoding either a small nuclear protein or a non-coding RNA; alternative splicing results in multiple transcript variants[3][6]. PRAC2 is part of a group of genes with tissue-enhanced or tissue-restricted expression, but its molecular function remains unclear—it may have roles in cell biology or tissue development, particularly in the prostate[4][1]. There is weak evidence suggesting PRAC2 might be implicated in cancer biology, most notably prostate cancer, but no definitive proof exists for a direct role in disease pathogenesis or as a therapeutic target[4][5]. PRAC2 is not classified as a receptor, enzyme, transporter, or transcription factor, and there are no approved drugs or well-described mechanisms of action, biomarker utility, or safety concerns linked to its modulation[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PRAC2 small nuclear protein (PRAC2).